TITLE

Taking a Second Look at Biotech

AUTHOR(S)
Santini, Laura
PUB. DATE
August 2003
SOURCE
Investment Dealers' Digest;8/4/2003, Vol. 69 Issue 31, p10
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the secondary stock offerings of the U.S.-based biotechnology companies as of August 2003. Factors responsible for the improvement of financial performance of biotechnology and pharmaceutical industry; Amount of money raised by ILEX Oncology Inc. in a secondary stock offering; Efforts of bankers to initiate deals among the biotechnology companies.
ACCESSION #
10593043

 

Related Articles

  • pharmaceuticals In Brief.  // Chemical Market Reporter;5/27/2002, Vol. 261 Issue 21, p8 

    Presents updates on the pharmaceutical industry as of May 2002. Establishment of Nephrx, a joint venture of Lyne Laboratories and Liberty Pharmaceutical; Filing of a supplemental biologics license application by Ilex Oncology to the U.S. Food and Drug Administration.

  • Company News. Jaquiss, Ian; Sellers, L.J. // Pharmaceutical Executive;Sep99, Vol. 19 Issue 9, p171 

    Presents articles pertaining to pharmaceutical companies in the United States. Definitive merger agreement executed by Teva Pharmaceuticals and Copley Pharmaceutical; Acquisition of Convergence Pharmaceuticals by ILEX Oncology; Retirement of John Urheim as vice chairman and chief executive...

  • Biotech stocks: Hard pills to swallow?  // Bank Investment Consultant;Dec99, Vol. 7 Issue 12, p51 

    Focuses on the debate over the issue of investing in biotechnology stocks. Good value of large cap pharmaceutical stocks; Opportunities brought by technological advances in biotechnology, gene therapy and drug discovery; Complications of investing in pharmaceuticals.

  • Human Genome Map Will Galvanize Biotech and Pharmaceutical Industries. Wagley, John // Investment Dealers' Digest;07/10/2000, Vol. 66 Issue 28, p24 

    Presents an overview of the performance of biotechnology and pharmaceutical stocks in the United States during the first six months of 2000. Expected impact of the announcement of the completion of the human genome map; Rise in alliances and mergers between biotechnology and pharmaceutical...

  • Stock Movers.  // BioWorld Today;2/24/2011, Vol. 22 Issue 37, p2 

    A list of significant stock changes in the biotechnology and pharmaceutical industries as February 23, 2011 is presented, including Nasdaq Biotechnology, Antisoma and Tengion Inc.

  • Ilex submits application for pediatric acute leukemia treatment.  // PharmaWatch: Biotechnology;December 2003, Vol. 2 Issue 12, p14 

    Reports on the submission of Ilex Oncology Inc.'s new drug application with the U.S. Food and Drug Administration for clofarabine, a drug for the treatment of acute leukemia. Presentation of the clinical trial of clofarabine; Clinical indications of the drug; Significance of the drug application...

  • Genzyme acquires Ilex Oncology in $1bn deal.  // PharmaWatch: Biotechnology;April 2004, Vol. 3 Issue 4, p18 

    Reports on the acquisition of Ilex Oncology Inc. by Genzyme Corp. Terms under the deal; Benefits of the agreement for both companies; Significance of the deal for the pharmaceutical biotechnology industry.

  • INDUSTRY UPDATE - Key Announcements.  // PharmaWatch: Cancer;June 2003, Vol. 2 Issue 6, p2 

    No abstract available.

  • Ilex Oncology shareholders approve merger with Genzyme Corporation.  // PharmaWatch: Biotechnology;August 2004, Vol. 3 Issue 8, p21 

    Shareholders in Ilex Oncology Inc. and Genzyme Corp. have voted unanimously to approve the proposed merger of the two companies at a special meeting held in Boston Massachusetts. The closing of the transaction remains subject to receipt of clearance by the U.S. Federal Trade Commission. Ilex and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics